{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:46:55Z","timestamp":1791902815348,"version":"4.3.4"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573448"],"award-info":[{"award-number":["82573448"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Esophageal cancer presents a formidable global health challenge, particularly when complicated by esophageal fistulas, which historically confer a dismal prognosis and severely limit therapeutic options. We report a challenging case of locally advanced esophageal squamous cell carcinoma (ESCC) complicated by an esophageal fistula that ultimately achieved a pathological complete response (pCR). The patient, a male in his 50s, presented with cough and dysphagia and was diagnosed with Stage IVA ESCC. Notably, an esophageal fistula was identified at the initial presentation, posing a threat to treatment. Aggressive enteral nutritional support via nasogastric tube placement and subsequent percutaneous endoscopic gastrostomy (PEG) was promptly initiated. This allowed the patient to successfully complete neoadjuvant therapy consisting of the anti-PD-1 antibody tislelizumab, paclitaxel, carboplatin, and concurrent intensity-modulated radiation therapy (IMRT). Following this multimodal regimen, the patient was reassessed as resectable following response to therapy status. Subsequent radical esophagectomy revealed no residual tumor cells in the primary lesion or dissected lymph nodes (ypT0N0M0), confirming pCR. Immunohistochemical analysis of pre-treatment biopsies demonstrated PD-L1 positivity and high infiltration of CD8+ T cells, suggesting that a robust immune-active microenvironment favored the efficacy of PD-1 blockade. This case underscores the feasibility of integrating immunotherapy with chemoradiotherapy in ESCC patients complicated by esophageal fistulas when supported by rigorous nutritional management.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1750544","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:52:02Z","timestamp":1770792722000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological complete response in esophageal squamous cell carcinoma complicated by malignant fistula via neoadjuvant immunotherapy, chemoradiotherapy, and nutritional support: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Nanxi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China","volume":"4","author":"Han","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"B2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12885-018-4486-3","article-title":"Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study","volume":"18","author":"Kawakami","year":"2018","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e69703","DOI":"10.1136\/bmjopen-2022-069703","article-title":"Retrospective cohort study on treatment modalities and survival time after esophageal fistula in patients with esophageal cancer in a regional cancer care center in China","volume":"13","author":"Xu","year":"2023","journal-title":"BMJ Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12885-025-13853-2","article-title":"A retrospective cohort study on radio\/chemotherapy and survival following esophageal fistula in esophageal cancer patients with prior radiotherapy","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg (London England)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e4291","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.1038\/s41467-024-51105-2","article-title":"Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:23:12Z","timestamp":1771928592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2026.1750544"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1750544","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1750544"}}